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Glucosamine HCl-based solid dispersions to enhance the biopharmaceutical
properties of acyclovir
Abstract
The objective of the work presented here was to assess the feasibility of using glucosamine HCl as a
solid-dispersion (SD) carrier to enhance the biopharmaceutical properties of a BCS class III/IV drug,
acyclovir (ACV). The solid-dispersions of acyclovir and glucosamine HCl were prepared by an ethanolbased solvent evaporation method. The prepared formulations characterized by photomicroscopy,
scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier transforms infrared
spectrophotometry (FTIR), powder x-ray diffractometry (PXRD) and drug content analysis. The functional
characterization of ACV-SD was performed by aqueous solubility evaluation, dissolution studies, fasted
versus fed state dissolution comparison, ex vivo permeability, and stability studies. Photomicroscopy and
SEM analysis showed different surface morphologies for pure ACV, glucosamine HCl and ACV-SD. The
physical-chemical characterization studies supported the formation of ACV-SD. A 12-fold enhancement in
the aqueous solubility of ACV was observed in the prepared solid dispersions, compared to pure ACV.
Results from in vitro dissolution demonstrated a significant increase in the rate and extent of ACV
dissolution from the prepared ACV-SD formulations, compared to pure ACV. The rate and extent of ACV
permeability across everted rat intestinal membrane were also found to be significantly increased in the
ACV-SD formulations. Under fed conditions, the rate and extent of the in vitro dissolution of ACV from the
formulation was appreciably greater compared to fasted conditions. Overall, the results from the study
suggest the feasibility of utilizing glucosamine HCl as a solid dispersion carrier/excipient for
enhancement of biopharmaceutical properties of acyclovir, and similar drugs with low solubility/
permeability characteristics.
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ABSTRACT

The objective of the work presented here was to assess the feasibility of using glucosamine HCl as a solid-dispersion (SD)
carrier to enhance the biopharmaceutical properties of a BCS class III/IV drug, acyclovir (ACV). The solid-dispersions of
acyclovir and glucosamine HCl were prepared by an ethanol-based solvent evaporation method. The prepared formulations
characterized by photomicroscopy, scanning electron microscopy (SEM), differential scanning calorimetry (DSC), Fourier
transforms infrared spectrophotometry (FTIR), powder x-ray diffractometry (PXRD) and drug content analysis. The
functional characterization of ACV-SD was performed by aqueous solubility evaluation, dissolution studies, fasted versus
fed state dissolution comparison, ex vivo permeability, and stability studies. Photomicroscopy and SEM analysis showed
different surface morphologies for pure ACV, glucosamine HCl and ACV-SD. The physical-chemical characterization studies
supported the formation of ACV-SD. A 12-fold enhancement in the aqueous solubility of ACV was observed in the
prepared solid dispersions, compared to pure ACV. Results from in vitro dissolution demonstrated a significant increase in
the rate and extent of ACV dissolution from the prepared ACV-SD formulations, compared to pure ACV. The rate and
extent of ACV permeability across everted rat intestinal membrane were also found to be significantly increased in the
ACV-SD formulations. Under fed conditions, the rate and extent of the in vitro dissolution of ACV from the formulation
was appreciably greater compared to fasted conditions. Overall, the results from the study suggest the feasibility of utilizing
glucosamine HCl as a solid dispersion carrier/excipient for enhancement of biopharmaceutical properties of acyclovir, and
similar drugs with low solubility/permeability characteristics.
KEY WORDS: Acyclovir, ACL, glucosamine HCl, solid dispersion, solubility, permeability, excipients

INTRODUCTION

Modern drug discovery techniques, which include high
throughput screening and combinatorial chemistry, have
generated new molecules with solubility characteristics
that result in lower and inconsistent oral bioavailability
(1). Over half of all newly discovered drugs appears
*Corresponding address: Vivek S. Dave, St. John Fisher College, Wegmans School
of Pharmacy, Rochester, NY, 14534, Tel: 1-585-385-5297, Fax: 1-585-385-5295,
E-mail: vdave@sjfc.edu
This Journal is © IPEC-Americas

to fall into biopharmaceutics classification system’s
(BCS) class II (↓ solubility, ↑ permeability), Class III
(↑ solubility, ↓ permeability) or class IV (↓ solubility, ↓
permeability) (2). These drugs exhibit dissolution and/
or permeation rate-limited absorption. For these drugs,
enhancement of dissolution rate and/or permeability
is vital to attain suitable blood concentration to
achieve optimal bioavailability for therapeutic effect
(3-5). Thus, for a formulation development team,
there is a consistent and well-justified need to explore
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approaches that improve the dissolution and/or
permeability characteristics of such drugs.
Among the popular approaches explored in
the past decade to achieve this goal include the
micronization of drugs, formulation of drugs into
liposomes, microspheres, microemulsions, inclusion
complexes, nanoparticles, self-micro emulsifying
drug delivery systems, solid dispersions, and other
non-traditional drug delivery systems (6-14). Among
these, formulating drugs into solid dispersions to
improve their biopharmaceutical properties has gained
widespread traction and acceptance. Solid dispersions
are typically formed by uniformly dispersing one, or
more, APIs into a hydrophilic matrix carrier using
thermal, mechanical, co-solubilizing or a combination
of one or more similar techniques (15, 16). Within a
solid dispersion, the solubility and permeability of the
API is reported to be improved by, a) the reduction
of particle size of the drug to sub-micron or smaller,
allowing increased surface area for dissolution, b)
the alteration of a crystalline drug to a high energy
amorphous state, and c) increasing wettability of the
drug particles in an aqueous environment (16, 17). The
development of a successful solid dispersion often
depends on the choice of the carrier material, as well
as, the processing method.
Acyclovir is an antiviral drug, commonly prescribed
for the treatment of infections caused by the herpes
simplex viruses (HSV-1 and HSV-2) and the varicellazoster virus. Depending on the available strength of the
tablets, acyclovir has been classified as either a BCS class
III or a class IV drug (18). Upon oral administration,
acyclovir exhibits low oral bioavailability (~15-30%)
(19). The low bioavailability of acyclovir is attributed to
its poor aqueous solubility, as well as, low permeability
(20-23). Therefore, acyclovir was selected as a model
drug for this study with the objective to improve its
dissolution and permeability characteristics.
Glucosamine is a naturally occurring aminomonosaccharide obtained from glucosamine6-phosphate via a hexosamine biosynthetic
pathway. Structurally, it is a 2-amino-2-deoxy-β-Dglucopyranose with the molecular formula (C6H13NO5).
This Journal is © IPEC-Americas

It is a non-toxic and a highly water-soluble (320 mg/
mL) compound (24, 25). Among its salts, that is
hydrochloride (HCl), sulfate and N-acetyl, the HCl salt
is pharmaceutically acceptable due to its high aqueous
solubility and physical stability. The hydrophilic nature
of glucosamine HCl is reported to improve drugs with
poor aqueous solubility and permeability by improving
particle wettability in an aqueous environment (26).
Despite its potential drug delivery optimizing benefits,
the usage and applications of glucosamine HCl as a
carrier in the designing of novel drug delivery systems
remains largely unexplored. In recent years, only a few
publications originating from the group of Al-Hamidi
et. al. have reported the potential for using glucosamine
HCl as a solid dispersion carrier (26, 27). While useful
and informative, these studies can be considered
insufficient in terms of material characterization and
functional analysis of the formulations.
Therefore this study describes a systematic and
comprehensive feasibility analysis of using glucosamine
HCl as a solid dispersion carrier for improving the
dissolution and/or permeability characteristics of
acyclovir. For the study, acyclovir solid dispersion
formulations (ACV-SD) with increasing ratios of
glucosamine HCl were prepared using an ethanol-based,
solvent-evaporation method. The prepared ACV-SD
were subjected to physical-chemical characterization
with scanning electron microscopy, particle size
and zeta potential analysis, thermal analysis, Fourier
transforms infrared spectroscopy, powder x-ray
diffractometry, aqueous solubility, and drug content
analysis. The ACV-SD were further characterized for
their functionality via dissolution and permeability
studies, and fasted- and fed- state dissolution studies.
Finally, the influence of controlled-storage conditions
on the functional attributes of ACV-SD was evaluated
by conducting a preliminary stability study for a period
of six months.
MATERIALS AND METHODS
Materials

Acyclovir was obtained from Zim Laboratories Ltd.,
Nagpur, India. D (+) Glucosamine hydrochloride was
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sourced from Sigma-Aldrich Corporation, St. Louis,
MO, USA. Dichloromethane, ethanol, glacial acetic acid,
soy lecithin, methanol, n-octanol, sodium hydroxide,
and sodium taurocholate were acquired from Loba
Chemical Pvt. Ltd., Mumbai, India. Calcium chloride,
glucose, magnesium sulfate, potassium chloride,
potassium dihydrogen phosphate, sodium chloride,
and sodium bicarbonate were sourced from Merck
Ltd. Mumbai, India. All other chemicals/solvents used
were of analytical grade and used as received.
Preparation of acyclovir solid dispersion (ACV-SD)

Solid dispersions of acyclovir (ACV-SD) using
glucosamine HCl as a carrier were prepared using
different drug:carrier ratios (1:1, 1:2, 1:3, 1:4, and
1:5) according to the method previously described by
Dhore et. al. (28). Briefly, acyclovir was weighed and
dissolved in 10 mL ethanol. The ethanolic solution
of acyclovir was then added to previously weighed
glucosamine HCl in a mortar and blended thoroughly.
The blending/trituration was continued until the
ethanol was completely evaporated, forming a uniform
dispersion. Complete evaporation of any residual
ethanol was ensured by vacuum drying the samples at
40°C for 12 hours. The dried ACV-SD sample powders
were stored in amber glass vials (flushed with nitrogen)
at controlled room temperature (25°C) until needed.
The composition of the prepared ACV-SD is shown
in Table 1.
Table 1 Composition of the prepared acyclovir-glucosamine
hydrochloride solid-dispersion formulations
FORMULATION

DRUG (MG)

CARRIER (MG)

ACV-SD1

100

100

ACV-SD2

100

150

ACV-SD3
ACV-SD4

100

100

200

250

ACV-SD5

100

300

Physical-chemical characterization of ACV-SD
Photomicroscopy and scanning electron microscopy
(SEM)

The preliminary microscopic assessment of pure
This Journal is © IPEC-Americas

ACV, glucosamine HCl and the prepared ACV-SD
was carried out using a digital microscope (Model:
DM2500, Leica Microsystems, Germany). The samples
for analysis were prepared by dispersing ~10 mg of
either the drug, the carrier or the prepared formulation
in 5 mL distilled water. A droplet from the uniformly
mixed dispersion was then placed on a clean glass slide
and observed under the microscope. The images of
the samples were captured at different resolutions.
Additionally, individual samples were also examined for
their surface characteristics using a scanning electron
microscope (Model: Supra® 55, Carl Zeiss NTS Ltd.,
Germany). Briefly, the sample (~50g) was spread as a
thin layer on a double-faced carbon tape, placed on
the aluminum platform, which was then placed in the
sample holder of the microscope. The sample was
then coated with a thin layer of gold (~400 A°) using
a sputter coater (Model: Supra® 55). The samples were
scanned at an accelerating voltage of 10 kV, and the
equipment-accompanied software (SmartSEM®, TV
mode) was used to develop and record the images at
different magnifications.
Particle size and zeta potential analysis

The particle size distribution of the prepared ACVSD was performed on a Photon Cross Correlation
Spectrometer (Model: NANOPHOX Sympatec,
GmbH, Clausthal-Zellerfeld, Germany) with dynamic
light scattering using a procedure reported by our
laboratory earlier (29). The test samples were prepared
by dispersing ACV-SD in deionized water. The analysis
was performed at an operating sensitivity of 1 nm to
10 µm, and the particle count rate was optimized by
the associated software.
The prepared ACV-SD were also analyzed for zeta
potential using a Nano Particle Analyzer (Model:
NanoPlusTM-2, Particulate system, Norcross, GA,
USA). The analysis was carried out at a controlled
temperature (25°C) and an operating range of -200 to
+200 mV.
Thermal analysis

To evaluate any interactions between ACV and
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glucosamine HCl, a differential scanning calorimeter
(Model: Q20, TA Instrument, Inc., New Castle, DE,
USA) was used to record the thermal behaviors of
pure ACV, pure glucosamine HCl, the physical mixture
(PM, 1:3) of pure ACV and glucosamine HCl, and the
prepared ACV-SD. Thermograms of these samples
were compared and analyzed. Individual samples (~ 2
mg) were press-sealed in aluminum pans and analyzed
on the equipment previously calibrated with an indium
standard. Each sample was subjected to a heating
cycle from 0°C to 400°C at a ramp rate of 10°C/min,
under a continuous purge of nitrogen (50 mL/min).
The universal analysis software (Version 4.5A, build
4.5.0.5, TA Instruments, Inc., New Castle, DE, USA)
accompanied by the instrument was used to analyze
and interpret the obtained thermograms.
Fourier transforms infrared spectroscopy (FTIR)

Pure ACV, glucosamine HCl, PM, and ACV-SD
samples were subjected to FTIR analysis in an attempt
to understand their chemical differences as well as any
interactions between the ACV and glucosamine HCl,
either in a physical mixture or within the prepared
dispersion. The spectra were collected using an FTIR
spectrophotometer (Model: FTIR-8300, Shimadzu,
Kyoto, Japan) following the procedure reported by
Telange et. al. (30), and compared in order to identify
the occurrence of any intermolecular interactions.
Powder x-ray diffractometry (PXRD)

The crystal characteristics of the drug, the carrier,
their physical mixture (1:3), and the prepared
solid dispersion were investigated by PXRD. The
diffractograms were obtained on a bench-top x-ray
diffractometer (MODEL: D8 ADVANCE, Bruker
AXS, Inc., Madison, WI, USA), using the method
reported previously by Telange et. al. (29).
Estimation of ACV content in ACV-SD

The ACV content in the prepared ACV-SD was
estimated spectrophotometrically, following a
procedure described by Chaudhary et. al. (31). The
appropriate quantity of ACV-SD powder (containing
This Journal is © IPEC-Americas

~100 mg ACV) was dissolved in 100 mL phosphate
buffer (0.05 M, pH 6.8). The resulting solution
was filtered (membrane filter, 0.45 µm), and after
relevant sequential dilutions, analyzed using a UVvisible spectrophotometer (MODEL: V-630, JASCO
International Co., Ltd., Tokyo, Japan) at 251 nm. The
sample absorbance values were compared against
those from a blank (a solution of glucosamine HCl in
phosphate buffer) to calculate the amount of free ACV
in the ACV-SD. The ACV content (%) incorporated
in the prepared SD formulations was calculated using
Equation 1.
ACV content (%)=

total ACV (mg)-free drug (mg)
= x 100
total ACV (mg)

Eq. 1

Aqueous solubility analysis

The aqueous solubilities of pure ACV, ACV in the
physical mixture, and ACV in the prepared dispersions
were determined using a procedure mimicking the one
described by Al-Hamidi et. al. (27). Excess amounts
of samples were individually dispersed in 10 mL
distilled water in screw-cap glass vials and agitated on
a rotary shaker (Model: RS-24 BL, REMI Laboratory
Instruments, Remi House, Mumbai, India) at 37°C for
24 hours. The dispersions were then filtered (0.45 µm),
diluted, and the absorbance of the resulting solutions
was measured on a UV-visible spectrophotometer
(MODEL: V-630, JASCO International Co., Ltd.,
Tokyo, Japan) at 251 nm. The absorbance values, after
comparison with a blank and a standard solution of
ACV, were used to calculate the aqueous solubility of
ACV.
Functional characterization of ACV-SD
In vitro dissolution studies

Comparative assessment of the release pattern of
pure ACV and ACV from ACV-SD was performed
using a USP Type II (paddle) dissolution equipment
(Model: TDT-08LX, Electrolab India Pvt. Ltd.,
Mumbai, India). Each dissolution run was conducted
by dispersing pure ACV (40 mg) or ACV-SD (~40
mg ACV) in the dissolution vessel containing freshly
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prepared phosphate buffer (900 mL, 0.05 N, pH 6.8)
maintained at 37°C. The experiment was carried out
for 120 minutes at 100 RPM stirring speed. Sample
aliquots for testing were collected at 10 minute intervals
and replaced with equal volumes of fresh medium.
The test samples, after filtration and appropriate
dilutions, were measured for absorbance using a UVvisible spectrophotometer (MODEL: V-630, JASCO
International Co., Ltd., Tokyo, Japan) at 251 nm. The
absorbance values, after comparison with a blank and
a standard solution of ACV, were used to calculate the
cumulative dissolution profiles of ACV and ACV-SD.
Influence of fasted versus fed-state media

The influence of fasted versus fed state on the dissolution
behavior of pure ACV and ACV-SD was assessed by
conducting dissolution tests using standard Fasted
(FaSSIF) and Fed-state (FeSSIF) dissolution media.
The media were prepared using the procedure reported
by Klein et. al. (32). The dissolution was performed
on a USP Type II (paddle) dissolution test apparatus
(Model: TDT-08LX, Electrolab India Pvt. Ltd.,
Mumbai, India). Each dissolution run was conducted
by dispersing pure ACV (100 mg) or ACV-SD (~100
mg ACV) in the dissolution vessel containing either
FaSSIF (500 mL) or FeSSIF (1000 mL) maintained at
37°C. The dissolution was carried out for 120 min at a
paddle stirring speed of 50 RPM. Aliquots of samples
were collected at 10 minute intervals for testing and
replaced with an equal volume of the blank medium.
The test samples, after filtration and appropriate
dilutions, were measured for absorbance on a UVvisible spectrophotometer (Model: V-630, JASCO
International Co., Ltd., Tokyo, Japan) at 248.2 nm
(FaSSIF) or 272 nm (FeSSIF). The absorbance values
were used to calculate the cumulative dissolution
profiles of ACV and ACV-SD in respective media.
Permeability across a biological membrane

The biological permeability of pure ACV and ACV in
the prepared dispersion was assessed using the everted
This Journal is © IPEC-Americas

rat intestine method previously reported by Dixit et. al.
(33). The details of the method, including the design
and assembly of the apparatus, the use of experimental
animals, and so on has been reported previously and
followed as described therein (34). Briefly, the isolated
intestinal membrane was mounted on the apparatus
filled with Krebs solution (250 mL) as a permeation
medium. The test sample solutions i.e., pure ACV
(100 µg/mL) or ACV-SD (~100 µg/mL), prepared
using Krebs solution, were placed in the apparatus on
the mucosal side of the membrane. The medium was
maintained at 37°C and continuously stirred at 25 RPM
for a period of 120 minutes. Aliquots of samples were
withdrawn at regular intervals from the serosal side
of the membrane, and after filtration and appropriate
dilutions, were measured for absorbance using a UVvisible spectrophotometer (MODEL: V-630, JASCO
International Co., Ltd., Tokyo, Japan) at 250.4 nm. The
obtained absorbance values were used to calculate the
cumulative permeability profiles of ACV and ACV-SD.
Preliminary stability assessment

The optimized ACV-SD formulation i.e., ACV-SD3
was evaluated for its functional stability upon storage
under controlled storage conditions (25°C at 60%
RH). The samples were packaged in screw-capped,
high-density polyethylene (HDPE), amber-colored
bottles, and stored in an environmental chamber
(Model: TS00002009, Mumbai, Maharashtra, India) for
a period of six months. At the end of six months, the
samples were retrieved and subjected to dissolution and
permeability studies using the respective procedures
described above.
Statistical analysis

The results are presented as mean ± standard deviation.
The statistical analysis for comparing differences
between test samples was performed using a one-way
analysis of variance (ANOVA) followed by a Dunnett’s
or a Students t-test. P values of ≤ 0.05 were considered
as a statistically significant difference.
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RESULTS AND DISCUSSION
Physical-chemical characterization of ACV-SD
Photomicroscopy and scanning electron microscopy
(SEM)

Microscopic images of pure ACV, pure glucosamine
HCl, and ACV-SD, captured at 20X magnification are
shown in Figure 1 (A, B, and C). Pure ACV (Figure 1A)
appeared as small, regular crystals with well-defined
geometric faces and edges. The morphology of these
crystals appeared to correspond to the monoclinic
polymorphic form V of ACV (35). The glucosamine
HCl particles (Figure 1B) appeared to be relatively
larger, globular particles with a smooth surface.
The particles of ACV-SD (Figure 1C) appeared as
non-uniform, clusters with ill-defined morphology.
The defining characteristics of pure ACV or pure
glucosamine HCl were absent in ACV-SD.

Further analysis of these particles using SEM
imaging confirmed the observations from the photomicroscopic images (Figure 1a, 1b, and 1c). Pure ACV
exhibited a crystalline, regular structure with geometric
angles (Figure 1a). Pure glucosamine HCL showed
larger particles with a rounded, smooth surface. The
ACV-SD particles appeared as irregular clusters/
aggregates formed as a result of the physical interaction
between ACV and glucosamine HCl.
Particle size and zeta potential analysis

The mean particle size and zeta potential are
considered relevant markers indicative of the physical
stability of sub-micron particles dispersed in a liquid
medium (29). Particles sizes ≤ 500 nm are known to
prefer endocytosis as a major pathway of transport
across biological membranes (36). The mean particle
size of the prepared ACV-SD was ~120 nm with a
polydispersity index (PDI) of 31.06 (Figure 2A). The

Figure 1 Photomicroscopy images of (A) pure acyclovir, (B) pure glucosamine HCl, and (C) acyclovir-glucosamine HCl solid dispersion.
Scanning electron microscopy images of (a) pure acyclovir, (b) pure glucosamine HCl, and (c) acyclovir-glucosamine HCl solid dispersion
(ACV-SD).
This Journal is © IPEC-Americas
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prepared formulation thus has a sub-micron particle
size and a narrow distribution.
Zeta potential (ζ) often indicates the relative physical
stability of multiparticulate, disperse systems. The
measured zeta potential value of the prepared ACVSD formulation was – 39.43 ± 0.23 mV (Figure 2B),
indicating that the prepared formulation dispersion
is relatively stable, and bereft of any aggregation

potential (28).
Thermal analysis

Physical interactions, if any, between the components
of a formulation, are generally quite conveniently
assessed using comparative thermal analysis. Such
interactions are generally revealed in the form of
appearance, disappearance, shifting, or changes

Figure 2 Particle size distribution (A) and zeta potential (B) of the prepared ACV-SD formulation.

This Journal is © IPEC-Americas
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in the onset and/or relative areas of the peaks as a
function of controlled temperature increases. These
interactions may indicate melting, degradation, and/
or incompatibilities between the components of the
formulation.
Figure 3 (A, B, C, and D) shows the thermograms
obtained from the DSC analysis of pure ACV, pure
glucosamine HCl, the physical mixture (PM, 1:3) of
pure ACV and glucosamine HCl, and the prepared
ACV-SD. The thermogram of pure ACV (Figure
3A) exhibited a sharp peak at ~256°C, indicative of

the melting temperature of ACV. Another minor
endothermic event was observed for pure ACV between
~60°C and ~ 175°C (not apparent in the figure). This
event may be attributed to the phase transition of
polymorphic hydrate form V to anhydrous form III
in the range of 65°C and 100°C, and thereafter from
form III to anhydrous form VI at higher temperatures.
These changes in the thermal characteristics of ACV
are not uncommon and have been reported earlier (9,
10, 37). The thermogram of glucosamine HCl (Figure
3B) revealed two, broad, fused endothermic peaks; a
larger peak with an onset at ~190°C and a smaller peak

Figure 3 DSC thermograms of (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of ACV and glucosamine HCl,
and (D) the prepared ACV-SD formulation.

This Journal is © IPEC-Americas
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at ~229°C. The first peak is likely associated with the
melting of glucosamine HCl, and the second, smaller
peak may be associated with its degradation. These
results are in agreement with previously published
reports (26, 27). The thermograms of the physical
mixture (Figure 3C) exhibited broad, fused peaks
similar to that of pure glucosamine HCl, along with the
disappearance of the melting peak of ACV. It is likely
that with increasing temperatures, glucosamine HCl
melted earlier at around 190°C and ACV dispersed/
dissolved in the carrier matrix in situ. The thermogram
of ACV-SD (Figure 3D) revealed broad, diffused
endothermic peaks that were uncharacteristic of either
pure ACV or pure glucosamine HCl. The absence of
defining peaks of ACV and glucosamine HCl in ACVSD thermogram is expected to owe the possibility that
ACV is molecularly dispersed into the carrier matrix,
resulting in partial amorphization of ACV.
Fourier transform infrared spectroscopy (FTIR)

The spectra obtained from the infrared analysis of
pure ACV, pure glucosamine HCl, the physical mixture
(PM, 1:3) of pure ACV and glucosamine HCl, and
the prepared ACV-SD are shown in Figure 4A, 4B,
4C, and 4D, respectively. For pure ACV (Figure 4A),
characteristic absorption bands were located at ~3622
cm-1 (primary amine) and 3411 cm-1 (secondary amine,
N-H stretching). Additional peaks typically associated
with ACV were found at ~1712 cm-1 (C=O stretching),
~1630 cm-1 and ~1609 cm-1 (amine), ~1483 cm-1 (O-H
stretching), and ~1347 cm-1 (C-H stretching). These
observations were consistent with previous findings
(10, 38). The FTIR spectrum of glucosamine HCl
(Figure 4B) exhibited a characteristic absorption peak
at ~3291 cm-1 (N-H and O-H stretching). Other peaks
related to glucosamine were observed at ~3000 cm-1
and 2881 cm-1 (-C-H stretching), ~1618 cm-1 and
1537 cm-1 (N-H bending), ~1140 cm-1 (asymmetric

Figure 4 FTIR spectra of (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of ACV and glucosamine HCl, and
(D) the prepared ACV-SD formulation.
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C-O-C stretching) and ~1094 cm-1 (C-O functional
group). These results were analogous to those reported
earlier (39). The spectrum of the physical mixture of
the drug and the carrier (Figure 4C) showed peaks
corresponding mostly to glucosamine HCl, albeit with
higher absorbance intensities. The higher ratio of
glucosamine HCl in the mixture can be attributed to
the observed predominance of glucosamine related
peaks. The FTIR plot of ACV-SD formulation (Figure
4D) was found to be significantly different compared to
those of the individual components. The characteristic
peaks associated with pure ACV and pure glucosamine
HCl were absent in this spectrum. Several absorption
peaks were observed in the region between 3300 cm-1
and 1085 cm-1. The presence of unique peaks in this
spectrum can be likely attributed to hydrogen bonding
between the N-H functional group of ACV and the
O-H group of glucosamine HCl, and the formation
of solid dispersion (10, 27). The formation of solid

dispersion not only helps in solubilizing the API into
the hydrophilic carrier but also likely prevents the
recrystallization of the drug in the glass solution (40).
Powder x-ray diffractometry (PXRD)

Powder x-ray diffractometry (PXRD) provides
useful information on the crystalline properties and
any polymorphic changes in the components of a
formulation. The diffractograms obtained from the
PXRD analysis of pure ACV, pure glucosamine HCl,
the physical mixture (PM, 1:3) of pure ACV and
glucosamine HCl, and the prepared ACV-SD are shown
in Figure 5 (A, B, C and D). The diffractogram of pure
ACV (Figure 5A) showed a sharp, high-intensity peak
at ~7° 2θ, related to ACV crystal structure. Other lowintensity peaks were observed at ~ 10.5°, 21°, 26°, and
29° on the 2θ scale. All these peaks are associated with
the polymorphic form V of ACV and in agreement with
earlier published reports (10). The diffraction pattern

Figure 5 The x-ray diffractograms of (A) pure ACV, (B) pure glucosamine HCl, (C) the physical mixture (1:3) of ACV and glucosamine
HCl, and (D) the prepared ACV-SD formulation.
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of glucosamine HCl (Figure 5B) exhibited several low
and high-intensity peaks in the region between 12°
2θ and 60° 2θ, along with a partial amorphous ‘halo’
pattern between 5° 2θ and 15° 2θ, indicating a mostly
crystalline nature of the carrier. The diffractogram was
similar to that reported previously in the literature (26).
The diffractogram of the physical mixture (Figure 5C)
showed a series of peaks between 7° 2θ and 43° 2θ.
These peaks appeared to those observed with pure
ACV and pure glucosamine HCl, albeit with lower
intensities for peaks associated with ACV. Finally,
the diffractogram of ACV-SD revealed peaks that
were of significantly lower in number and intensities
compared to the pure components (Figure 5D). The
diffractogram appeared to retain the characteristic
peaks of the carrier, whereas, ACV-related peaks were
greatly minimized. It is likely that ACV is partially
amorphized in the prepared solid dispersion.
Estimation of the ACV content in ACV-SD

The ACV content in the prepared ACV-SD is
represented as % ACV incorporated in Table 2. For
all ACV-SD formulations, the ACV content was found
to be > 95% w/w. The formulation ACV-SD3 (drugcarrier ratio of 1:3) showed the highest incorporation
efficiency (98.17 ± 0.49 %) and was used as an optimal
formulation for most of the characterization studies.
The high incorporation efficiency of ACV in the
prepared formulation supported the selection of carrier
and the robustness of the formulation approach.

analysis of pure ACV, the physical mixtures of ACV
and glucosamine HCl, and the prepared ACV-SD
formulations are presented in Table 3. Pure ACV
exhibited aqueous solubility of ~14 µg/mL. This is
not surprising, as ACV is a known BCS Class III (↑
solubility, ↓ permeability) or class IV (↓ solubility, ↓
permeability) drug (18). The results are in agreement
with previously published aqueous solubility values for
ACV (9, 41). The solubilities of ACV in the physical
mixtures ranged between 82 and 85 µg/mL. These
values represented a nearly 6-fold higher solubility
of ACV in the physical mixture compared to that of
ACV alone. A close association of the water-soluble
carrier resulting in an increased wetting efficiency of
ACV particles in the aqueous medium is a likely cause
for the observed higher aqueous solubility of ACV in
the physical mixture. Among the physical mixtures,
ACV-SD3 (drug-carrier ratio of 1:3) exhibited the
highest observed solubility of ACV. Further increase
in the ratio of carrier probably restricted ACV particles
access to water, resulting in the observed modest
decrease in ACV solubility (27). The prepared ACV-SD
formulations exhibited significantly higher solubilities
of ACV, compared to that of pure ACV or ACV in
the physical mixtures. The solubilities of ACV in these
formulations ranged between 165 and 191 µg/mL.
These results represented a nearly 12-fold increase in
the solubility of ACV compared to that of ACV alone,
Table 3 Aqueous solubility of pure acyclovir, acyclovir in physical
mixture (PM), and acyclovir in the prepared solid-dispersions

Aqueous solubility analysis

FORMULATION

AQUEOUS SOLUBILITY (μg/mL)*

The results obtained from the aqueous solubility

Pure acyclovir

13.91 ± 0.02

PM-1

82.25 ± 0.03

Table 2 Drug content of acyclovir in prepared solid-dispersion
formulations

PM-2

84.59 ± 0.02

FORMULATION

PM-3

85.11 ± 0.08

PM-4

83.27 ± 0.04

DRUG CONTENT (%, w/w)*

PM-5

84.40 ± 0.03

ACV-SD1

95.30 ± 0.65

ACV-SD1

165.15 ± 0.02

ACV-SD2

97.21 ± 1.32

ACV-SD2

171.28 ± 0.08

ACV-SD3

98.17 ± 0.49

ACV-SD3

191.33 ± 0.06

ACV-SD4

96.10 ± 1.01

ACV-SD4

183.49 ± 0.06

ACV-SD5

180.36 ± 0.07

ACV-SD5

96.44 ± 1.20

*

All results are expressed as mean ± Std. Dev., n=3

All results are expressed as mean ± Std. Dev., n=3

*
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and a 2-fold increase compared to that of ACV in the
physical mixture. The solubilities of ACV within these
formulations followed a trend similar to that observed
with the physical mixtures. The observed enhanced
aqueous solubility of ACV in these formulations may
be attributed to carrier-assisted modifications of the
physical-chemical properties of ACV such as changes
in the particle size, morphology, and polymorphic state
(26).
Functional characterization of ACV-SD
In vitro dissolution studies

The comparative dissolution profiles of pure ACV and
the ACV-SD formulations prepared using different
drug-carrier ratios, in phosphate buffer (0.05 M, pH
6.8) are represented in Figure 6. Pure ACV exhibited
an initial rapid dissolution (~30% in 10 minutes),
followed by a steady, zero-order release over a period
of 2 hours. At the end of the dissolution period, the
extent of cumulative ACV dissolution was recorded at

~62%. The relatively lower dissolution efficiency of
pure ACV is attributable to its low aqueous solubility.
The rate and extent of ACV dissolution from the
prepared ACV-SD formulations followed the trend
observed with the solubility studies, i.e., cumulative
rate and extent of ACV dissolution increased in
formulations with increasing drug-carrier ratio, up to
the ratio of 1:3. For formulations with a drug-carrier
ratio of 1:4 and 1:5 the cumulative dissolution of ACV
was observed to be relatively slower and to a lesser
extent. This is possibly due to the higher concentration
of carrier inhibiting the access of ACV particles to the
dissolution media (27). ACV-SD3 (drug-carrier ratio of
1:3) exhibited the highest observed rate and extent of
ACV dissolution (~94%). Earlier studies suggested that
solvent-evaporation-method-based solid dispersions
produce high energy solid-state formulations by partial
amorphization of drug particles, which increases the
dissolution rate of drugs (17). Another possibility for
explaining enhanced aqueous solubility may be the
hydrophilic nature of glucosamine HCl increasing the

Figure 6 The comparative in vitro dissolution profiles of ACV and ACV-SD3 formulations.
This Journal is © IPEC-Americas

September 2019

J. Excipients and Food Chem. 10 (3) 2019

76

Original Article
wettability of dispersed ACV particles in ACV-SD (26).
Influence of fasted versus fed state media

Figure 7 shows a comparison of the dissolution
profiles of pure ACV and that of ACV from ACVSD3 formulation as tested in FaSSIF (fasted) and
FeSSIF (fed) media. The efficiency of the dissolution
of pure ACV was found to be lower in fasted
conditions compared to that in fed conditions. At
the end of the 2-hour dissolution period, only about
43% of pure ACV had dissolved. In fed conditions,
there was a modest, albeit significant increase in the
efficiency of ACV dissolution (~64% at the end of
2 hours). Positive food effects on the dissolution of
drugs with low aqueous solubility have been reported
earlier (32, 42). The rate and extent of ACV release
from ACV-SD3 were found to be higher in both fasted
and fed conditions compared to that of pure ACV. In
fasted conditions ~76%, and in fed conditions ~84%
ACV was released at the end of the 2-hour dissolution

period. These results correlated well with those
obtained from the solubility analysis and the in vitro
dissolution studies.
Permeability across a biological membrane

The comparative permeabilities of pure ACV and
ACV-SD formulations across a biological membrane,
as evaluated by the everted rat intestine model are
shown in Figure 8. After the 2-hour testing period,
only about 42% of pure ACV had permeated across
the membrane. ACV is reported at a BCS class III or
IV drug (low permeability), and thus the results are
consistent with those published previously (8, 18).
The permeability profiles of ACV from all ACVSD formulations were found to be relatively higher
compared to that of pure ACV. The permeability
of ACV from these formulations followed the trend
observed with the results obtained from solubility
and dissolution studies. In general, the rate and
extent of ACV permeability increased with increasing

Figure 7 The influence of fasted and fed-state conditions on the dissolution behavior of pure ACV and the ACV-SD formulations.
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Figure 8 The comparative ex vivo permeability profiles of the ACV and ACV-SD formulations.

drug-polymer ratio up to 1:3. ACV permeability was
observed to be lower for formulations with a drugcarrier ratio of 1:4 and 1:5. ACV-SD3 (drug-carrier
ratio of 1:3) exhibited the highest observed efficiency
of ACV permeability.
Preliminary stability assessment

The results obtained from the preliminary stability
assessment of the selected ACV-SD3 formulation was
stored at controlled temperature (25°C) and relative
humidity (60 ± 5% RH) for 6 months are shown in
Figure 9. Figure 9A shows a comparison of dissolution
profiles of ACV-SD3 at day 0 and day 180 (6 months).
It was observed that while the drug release from the
180-day sample followed a pattern similar to that
of day 0 sample, there was a noticeable decrease in
the efficiency of ACV dissolution at the end of
the duration of the study. Figure 9B compares the
permeability profiles of ACV-SD3 at day 0 and day 180.
Similar to the dissolution results, there was a noticeable
This Journal is © IPEC-Americas

decrease in the efficiency of ACV permeability for the
samples stored for 180 days, whilst the permeability
profile followed matching patterns. The reasons for
this shift in the dissolution and permeability of ACVSD are currently unclear. It is possible that the storage
conditions, mainly the relative humidity have had an
influence on the physical-chemical properties of ACV
or the solid dispersion. Further characterization of the
stored samples is currently underway.
CONCLUSIONS

The present study aimed to study the feasibility of
utilizing a relatively unexplored, hydrophilic excipient,
glucosamine HCl as a solid-dispersion carrier with the
goal of enhancing the biopharmaceutical properties
of drugs with low aqueous solubility. Solid dispersion
based formulations of acyclovir combined with
glucosamine HCl were successfully prepared using a
previously established solvent-evaporation method.
The prepared formulations were characterized for
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Figure 9 The effect of controlled storage conditions (25°C/60% RH, 180 days) on (A) dissolution and (B) permeability of ACVSD3.
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their physical and functional properties using various
analytical methods. The prepared ACV-glucosamine
HCl solid dispersions demonstrated marked increases
in aqueous solubility, dissolution, and permeability of
acyclovir compared to the pure drug. The prepared
solid dispersions were not found to be drastically
unstable, the storage conditions appeared to have a
modest influence on the physical-chemical properties
of either the drug or the formulation. While the nature
of this influence is unclear, further characterization
of the stored samples is warranted. The study overall
demonstrates the feasibility of utilizing glucosamine
HCl as a potential solid-dispersion carrier to improve
the biopharmaceutical properties of drugs with low
solubility and/permeability characteristics.
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